Pharming Group N.V.'s latest marketcap:
As of 06/25/2025, Pharming Group N.V.'s market capitalization has reached $740.76 M. According to our data, Pharming Group N.V. is the 11218th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 740.76 M |
| Revenue (ttm) | 344.08 M |
| Net Income (ttm) | -15,140,488.08 |
| Shares Out | 683.93 M |
| EPS (ttm) | -0.02 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/31/2025 |
Pharming Group N.V.'s yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/25/2025 | €740.76 M | -0.7% | 11218 |
| 12/31/2024 | €627.48 M | -9.08% | 11256 |
| 12/29/2023 | €690.16 M | -2.41% | 10256 |
| 12/30/2022 | €707.22 M | 40.66% | 9783 |
| 12/31/2021 | €502.78 M | -38.05% | 12500 |
| 12/31/2020 | €811.61 M | -17.99% | 8007 |
| 12/31/2019 | €989.6 M | 110.2% | 6442 |
| 12/31/2018 | €470.79 M | -24.87% | 8734 |
| 12/29/2017 | €626.64 M | 533.86% | 8444 |
| 12/30/2016 | €98.86 M | -14.9% | 15788 |
Company Profile
About Pharming Group N.V.
Pharming Group N.V. is a biopharmaceutical company specializing in the development and commercialization of protein replacement therapies and precision medicines for rare diseases. The company operates in the United States, Europe, and internationally.
Key Products
- RUCONEST – A recombinant C1 esterase inhibitor for treating acute hereditary angioedema (HAE) attacks in adults and adolescents.
- Joenja (leniolisib) – An oral small molecule PI3Kẟ inhibitor for activated phosphoinositide 3-kinase delta syndrome.
Pipeline Development
The company is advancing OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for HAE treatment.
Strategic Collaborations
- Development and license agreement with Novartis.
- Strategic partnership with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105.
Company Background
Founded in 1988, Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Frequently Asked Questions
-
What is Pharming Group N.V.'s (AMS-PHARM) current market cap?As of 06/25/2025, Pharming Group N.V. (including the parent company, if applicable) has an estimated market capitalization of $740.76 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Pharming Group N.V. (AMS-PHARM) rank globally by market cap?Pharming Group N.V. global market capitalization ranking is approximately 11218 as of 06/25/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.